NK92 Expressing Anti-BCMA CAR and Secreted TRAIL for the Treatment of Multiple Myeloma: Preliminary In Vitro Assessment publication / By David Žihala
Tuning CARs: recent advances in modulating chimeric antigen receptor (CAR) T cell activity for improved safety, efficacy, and flexibility publication / By David Žihala
Deubiquitinase OTUD1 Resolves Stalled Translation on polyA and Rare Codon Rich mRNAs publication / By David Žihala
Insight into the mechanism of CD34+ cell mobilisation impairment in multiple myeloma patients treated with anti-CD38 therapy publication / By David Žihala
Transcriptome Analysis of Diffuse Large B-Cell Lymphoma Cells Inducibly Expressing MyD88 L265P Mutation Identifies Upregulated CD44, LGALS3, NFKBIZ, and BATF as Downstream Targets of Oncogenic NF-κB Signaling publication / By David Žihala
Limited efficacy of daratumumab in multiple myeloma with extramedullary disease publication / By wordpress
Expansion, and Unique Pretreatment of Allogeneic Human Natural Killer Cells with Anti-CD38 Monoclonal Antibody for Efficient Multiple Myeloma Treatment publication / By wordpress
Mutation landscape of multiple myeloma measurable residual disease: identification of targets for precision medicine publication / By wordpress
The deubiquitinase OTUD1 regulates immunoglobulin production and proteasome inhibitor sensitivity in multiple myeloma publication / By wordpress
